Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029627 · ClinicalTrials.gov registry record
Brain Receptors in Sympathetic Nervous System Regulation
A clinical trial, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 200
- Enrollment target
NCT00029627 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 200 participants.
The verdict
NCT00029627 has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the role of brain receptors called alpha2-adrenoreceptors in regulating the sympathetic nervous system, which maintains the supply of blood and fuel to the body's organs in times of stress, fear, anger, or exercise. Alpha(2)-adrenergic receptors (alpha(2)-AR) play a role in a variety of physiological functions. There are three subtypes of alpha(2)-ARs, and their differences are unknown. This study will examine the functional roles of these three subtypes by comparing the behavioral, biochemical, psychophysiological, and autonomic function effects of the alpha(2)-AR drugs clonidine and yohimbine. Participants in this study will undergo a physical examination, electrocardiogram (ECG), and blood, urine, and saliva tests. Women will have hormone tests to determine the time of their last period and the time of their next ovulation. Participants will undergo neuropsychological testing and other procedures.
Interventions
- DRUG Yohimbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2002-01 |
| Est. Completion | 2004-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00029627
The ClinicalTrials.gov registry entry for NCT00029627 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Yohimbine is the first listed.
NCT00029627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00029627 about?
NCT00029627 is a clinical study titled "Brain Receptors in Sympathetic Nervous System Regulation". The purpose of this study is to investigate the role of brain receptors called alpha2-adrenoreceptors in regulating the sympathetic nervous system, which maintains the supply of blood and fuel to the body's organs in times of stress, fear, anger, or exercise. Alpha(2)-adrenergic receptors (alpha(2)...
What is the current status of trial NCT00029627?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2002-01. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00029627?
The interventions under investigation include: Yohimbine (DRUG).
Who is sponsoring clinical trial NCT00029627?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.